Drug Trial Radar · NCT05387525
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
447
Actual
Start
Oct 24, 2022
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- May 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the incidence of biopsy confirmed invasive squamous cell carcinoma (SCC) in the selected treatment field (TF) after administration of topical tirbanibulin 10 milligram (mg)/gram (g) ointment or diclofenac sodium 3 percent (%) gel over the 3-year study period.
Conditions
- Keratosis, Actinic
Interventions
Tirbanibulin (Klisyri®) 10 mg/g ointmentDrug
Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).
Diclofenac Sodium 3% GelDrug
Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Histologically Confirmed Invasive Squamous Cell Carcinoma (SCC) in the Treatment Field (TF)Time frame: Up to 3 years
Locations
49 sites in 6 countries. Site status is shown where the registry gives one.
Almirall Investigation Site 102
Lille, France
Almirall Investigation Site 103
Marseille, France
Almirall Investigation Site 104
Nice, France
Almirall Investigational Site 106
Paris, France
Almirall Investigational Site 105
Rouen, France
Almirall Investigational Site 101
Saint-Priest-en-Jarez, France
Almirall Investigational Site 205
Augsburg, Germany
Almirall Investigational Site 211
Bad Bentheim, Germany
Almirall Investigation Site 201
Bochum, Germany
Almirall Investigational Site 214
Bochum, Germany
Almirall Investigational Site 212
Bonn, Germany
Almirall Investigational Site 208
Detmold, Germany
Almirall Investigational Site 210
Dresden, Germany
Almirall Investigational Site 204
Erlangen, Germany
Almirall Investigational Site 206
Hamburg, Germany
Almirall Investigational Site 213
Hamburg, Germany
Almirall Investigational Site 207
Marburg, Germany
Almirall Investigational Site 209
Merzig, Germany
Almirall Investigation Site 202
Recklinghausen, Germany
Almirall Investigational Site 309
Arezzo, Italy
Almirall Investigational Site 302
Brescia, Italy
Almirall Investigational Site 304
Genova, Italy
Almirall Investigational Site 308
Modena, Italy
Almirall Investigational Site 301
Naples, Italy
Almirall Investigational Site 303
Reggio Emilia, Italy
Almirall Investigational Site 305
Roma, Italy
Almirall Investigational Site 306
Roma, Italy
Almirall Investigational Site 307
Roma, Italy
Almirall Investigational Site 310
Rozzano, Italy
Almirall Investigational Site 403
Lublin, Poland
Almirall Investigational Site 406
Rzeszów, Poland
Almirall Investigational Site 407
Warsaw, Poland
Almirall Investigational Site 401
Wroclaw, Poland
Almirall Investigational Site 402
Wroclaw, Poland
Almirall Investigational Site 502
Barcelona, Spain
Almirall Investigational Site 508
Barcelona, Spain
Almirall Investigational Site 510
Barcelona, Spain
Almirall Investigational Site 507
Granada, Spain
Almirall Investigational Site 509
Granada, Spain
Almirall Investigational Site 503
Madrid, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.